title: Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World.
authors.affiliation: Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
authors.forename: Sham
authors.initials: S
authors.lastname: Mailankody
authors.affiliation: Division of Hematology Oncology, Knight Cancer Institute, Portland, Oregon3Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland.
authors.forename: Vinay
authors.initials: V
authors.lastname: Prasad
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015415:Biomarkers; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D017277:Drug Approval / Q000331:legislation & jurisprudence / Q000458:organization & administration; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000401:mortality*; D018401:Sample Size; D016019:Survival Analysis; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers